CASI Pharma rises on strong cancer drug sales

CASI Pharmaceuticals

12/11/2021 16:16

** Shares of drugmaker  CASI.O  up ~1% at $1.06
    ** CASI Q3 revenue jumps 93% to $8.1 mln, driven by strong
sales of its intravenous drug, Evomela, for treating a type of
plasma cell cancer  urn:newsml:reuters.com:*:nPnqCPWda   
    ** "We remain confident in our guidance for our full-year
2021 revenue growth to exceed 2020 revenues by over 80%" - CEO
Wei-Wu He
    ** Net loss narrowed to $10.2 mln, or 7 cents per share,
from $17 mln, or 14 cents per share, a year earlier 
    ** All 4 brokerages covering the stock, rate it "buy" or
higher ; their median PT is $4 - Refinitiv data
    ** Including session move, stock down 64.07% YTD

    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))